Xolair 300 MG/2 ML syringe 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26FFBV4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $18,273
Award facts
- Contract value 100% obligated
- $18,273.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $18,273 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 ml syringes. The award, issued on January 7, 2026, with an ultimate completion date of January 29, 2026, contains no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group will perform this delivery order at its Park Ridge facility and supply the biologic immunosuppressant medication to support Department of Defense pharmaceutical supply requirements.
This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a comprehensive $30.3 billion acquisition strategy established to provide diverse pharmaceutical products and medical consumables to military healthcare facilities worldwide. The parent IDC, valued at $499,999,999 with a completion date of December 31, 2036, authorizes DLA to issue firm fixed-price delivery orders for branded and generic prescription drugs, biologics, and medical supplies. As a multiple-award prime vendor contractor under this program, DMS Pharmaceutical Group has demonstrated substantial federal contracting activity and capability to fulfill specialized pharmaceutical requirements across the Department of Defense's global medical system.
Quick answers
Who was awarded contract SPE2DR26FFBV4?
SPE2DR26FFBV4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 7, 2026.
How much is contract SPE2DR26FFBV4 worth?
The government has obligated $18,273 on SPE2DR26FFBV4.
Is contract SPE2DR26FFBV4 an order under another contract?
Yes. SPE2DR26FFBV4 is a delivery order under SPE2DR25D9239, an indefinite delivery contract.
Was contract SPE2DR26FFBV4 competed?
The extent of competition for SPE2DR26FFBV4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award